{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T07:13:33Z","timestamp":1758266013330},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2007,8,9]],"date-time":"2007-08-09T00:00:00Z","timestamp":1186617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:p> <jats:bold>What is already know about this subject<\/jats:bold> <\/jats:p><jats:p>\u2022\u2002Screening of the population may result in medicalization.<\/jats:p><jats:p>\u2022\u2002There is no report about the effect of a health screening programme on drug prescribing.<\/jats:p><jats:p> <jats:bold>What this study adds<\/jats:bold> <\/jats:p><jats:p>\u2022\u2002Screening of the general population for cardiovascular risk factors does not lead to more drug prescribing, for either screening\u2010related or screening\u2010unrelated drugs.<\/jats:p><jats:p>\u2022\u2002The incidence of drug use increases in screened subjects with high risk, but only for drugs related to the purpose of screening.<\/jats:p><jats:p>\u2022\u2002For screening to be successful, i.e. increased drug use in the detected diseased subjects, it has to be performed in a population expected to be at increased risk.<\/jats:p><jats:p><jats:bold>Aim<\/jats:bold> To evaluate the effect of a cardio\u2010renal screening programme on desired and undue drug use.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> Data from the PREVEND cohort (Prevention of REnal and Vascular ENd\u2010stage Disease) were used. The drug use of screened (randomly) selected subjects (<jats:italic>n<\/jats:italic>\u2003=\u20032650) was compared with unscreened subjects, matched for age and sex (<jats:italic>n<\/jats:italic>\u2003=\u200310\u2003434). Drug use in the overall PREVEND cohort, enriched for albuminuria (<jats:italic>n<\/jats:italic>\u2003=\u20036751), was also studied. Screening\u2010related drugs (antihypertensive, antilipidaemic, antidiabetic and antithrombotic) were selected, as well as screening\u2010unrelated drugs (benzodiazepines, drugs for acid\u2010related disorders and painkillers). Time to first prescription after screening is presented as Kaplan\u2013Meier curves.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> After 6.5\u2003years of follow\u2010up, the incidence of drug use was not significantly different between the screened, randomly selected and unscreened cohorts. Antihypertensives were used by 21.5 and 20.8%, respectively; antilipidaemic 12.8 and 10.2%, antidiabetics 4.0 and 3.9%, and antithrombotic 11.4 and 12.0%. Screening\u2010unrelated drugs were used at comparable frequencies. Compared with the unscreened cohort, screening\u2010related drugs were prescribed more frequently for subjects in the enriched cohort (25.8, 15.5, 5.5 and 13.5% for antihypertensive, antilipidaemic, antidiabetic and antithrombotic, respectively), whereas screening\u2010unrelated drugs were used at comparable frequencies.<\/jats:p><jats:p><jats:bold>Conclusions<\/jats:bold> The incidence of drug use did not differ between the screened, randomly selected and unscreened cohorts. Screening does not lead to more drug prescription, thus arguing against the fear of undue medicalization after screening. The data also show that, for screening to be successful, it should be performed in a targeted population, such as one enriched for albuminuria.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2007.02988.x","type":"journal-article","created":{"date-parts":[[2007,8,10]],"date-time":"2007-08-10T08:05:17Z","timestamp":1186733117000},"page":"810-818","source":"Crossref","is-referenced-by-count":5,"title":["The effect of screening for cardio\u2010renal risk factors on drug use in the general population"],"prefix":"10.1111","volume":"64","author":[{"given":"Jarir","family":"Atthobari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron T.","family":"Gansevoort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sipke T.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul E.","family":"De Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lolkje T. W.","family":"De Jong\u2010van den Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"PREVEND study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/18.1.10"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440420033005"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1520-7560(2000)9999:9999<::AID-DMRR122>3.0.CO;2-W"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)12323-7"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.3122\/15572625-11-1-72"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/1467-8519.00135"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.314.7080.533"},{"key":"e_1_2_6_9_2","first-page":"2","article-title":"Interventions to influence people's experience of screening","author":"Bastian H","year":"1999","journal-title":"The Cochrane Library"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001212"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyh014"},{"key":"e_1_2_6_12_2","first-page":"890","article-title":"Medicalisation of risk factors","volume":"324","author":"Gotzsche PC.","year":"2002","journal-title":"BMJ"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12655-4"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mjt.0000174345.59177.9b"},{"key":"e_1_2_6_15_2","first-page":"S26","article-title":"Managing the cost of cardiovascular prevention in primary care","volume":"90","author":"Evans N.","year":"2004","journal-title":"Heart Suppl"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7404.1419"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-005-6127-8"},{"key":"e_1_2_6_18_2","first-page":"207","article-title":"Effects of a screening program for hypertension in a community","volume":"46","author":"Radice M","year":"1991","journal-title":"Acta Cardiol"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.09408.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/3-540-39949-6_25"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000031732.78052.81"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V11101882"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.02011.x"},{"key":"e_1_2_6_24_2","unstructured":"WHO Collaborating Cebtre for Drugs Statistics Methodology.ATC\/DDD Index 2006.Available athttp:\/\/www.whocc.no\/atcddLast accessed9 January 2006."},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.542290"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.15.1868"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050360"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(96)00267-3"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.15.2055"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.4.382"},{"key":"e_1_2_6_31_2","first-page":"1","article-title":"Special report: the publication of new evidence and effect on physician prescribing behaviors","volume":"19","author":"Technology Evaluation Center.","year":"2004","journal-title":"Assessment Program"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000013862.13962.1D"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2001.00833.x"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/154.10.891"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.722"},{"key":"e_1_2_6_36_2","first-page":"619","article-title":"Indications for propensity scores and review of their use in pharmacoepidemiology","volume":"50","author":"Lau HS","year":"1997","journal-title":"J Clin Pharmacol"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2007.02988.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2007.02988.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T07:32:54Z","timestamp":1697441574000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2007.02988.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,9]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["10.1111\/j.1365-2125.2007.02988.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2007.02988.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"type":"print","value":"0306-5251"},{"type":"electronic","value":"1365-2125"}],"subject":[],"published":{"date-parts":[[2007,8,9]]}}}